LSC - 2021 - Modeling idiopathic pulmonary fibrosis using induced pluripotent stem cell-derived alveolar epithelial organoids
P. Victoria, S. Monkley (susan.monkley1@astrazeneca.com / Research and Early Development, R. & Immunology, B. R&D, A. , G. , S. , M. Tammia (markus.tammia@astrazeneca.com / Research and Early Development, R. & Immunology, B. R&D, A. , G. , S. , K. Öst (karolina.ost@astrazeneca.com / Research and Early Development, R. & Immunology, B. R&D, A. , G. , S. , C. Overed-Sayer (catherine.overed-sayer@astrazeneca.com / Research and Early Development, R. & Immunology, B. R&D, A. , C. , U. Kingdom,Cambridge), P. Hazon (petra.hazon@astrazeneca.com / Research and Early Development, R. & Immunology, B. R&D, A. , G. , S. , D. E Wagner (darcy.wagner@med.lu.se / Department of Experimental Medical Sciences, L. Bioengineering and Regeneration, L. University, L. , S. Wallenberg Center for Molecular Medicine, L. University, L. , S. Lund Stem Cell Center, L. University, L. , S. , L. A Murray (lynne.murray1@astrazeneca.com / Research and Early Development, R. & Immunology, B. R&D, A. , C. , U. Kingdom,Cambridge)
Source: Virtual Congress 2021 – In vitro modelling of lung disease: reach out to the next dimension
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
P. Victoria, S. Monkley (susan.monkley1@astrazeneca.com / Research and Early Development, R. & Immunology, B. R&D, A. , G. , S. , M. Tammia (markus.tammia@astrazeneca.com / Research and Early Development, R. & Immunology, B. R&D, A. , G. , S. , K. Öst (karolina.ost@astrazeneca.com / Research and Early Development, R. & Immunology, B. R&D, A. , G. , S. , C. Overed-Sayer (catherine.overed-sayer@astrazeneca.com / Research and Early Development, R. & Immunology, B. R&D, A. , C. , U. Kingdom,Cambridge), P. Hazon (petra.hazon@astrazeneca.com / Research and Early Development, R. & Immunology, B. R&D, A. , G. , S. , D. E Wagner (darcy.wagner@med.lu.se / Department of Experimental Medical Sciences, L. Bioengineering and Regeneration, L. University, L. , S. Wallenberg Center for Molecular Medicine, L. University, L. , S. Lund Stem Cell Center, L. University, L. , S. , L. A Murray (lynne.murray1@astrazeneca.com / Research and Early Development, R. & Immunology, B. R&D, A. , C. , U. Kingdom,Cambridge). LSC - 2021 - Modeling idiopathic pulmonary fibrosis using induced pluripotent stem cell-derived alveolar epithelial organoids. 2051
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: